Rahul Kakkar Joins Flagship Pioneering and Quotient Therapeutics as CEO
Investor - People | Apr 29, 2025 | Flagship Pioneering Inc
Flagship Pioneering, a leading bioplatform innovation company, and Quotient Therapeutics, known for pioneering somatic genomics, announced the appointment of Rahul Kakkar, M.D., as CEO-Partner at Flagship Pioneering and CEO at Quotient Therapeutics. Dr. Kakkar brings a wealth of experience in biotechnology, having previously served as President and CEO of Tome Biosciences and leading Pandion Therapeutics through its successful IPO and subsequent acquisition by Merck for $1.85 billion. At Quotient, he succeeds Jake Rubens, Ph.D., who will remain on the board as the company continues to expand its groundbreaking somatic genomics platform targeting novel drug discovery across various diseases. The appointment signifies a pivotal step for both Flagship and Quotient as they aim to leverage Kakkar's expertise to unlock the potential of somatic genomics in developing transformative medicines.
Sectors
- Biotechnology
- Healthcare
Geography
- United States – Flagship Pioneering is based in Cambridge, Massachusetts, and Quotient Therapeutics has research sites in the US, making the US a central geography.
- United Kingdom – Quotient Therapeutics has established research sites in the UK, highlighting its geographical importance.
Industry
- Biotechnology – The article focuses on Quotient Therapeutics, a company pioneering in somatic genomics, an advanced approach in biotechnology for drug discovery.
- Healthcare – Dr. Kakkar's background in developing medicines and the therapeutic focus of Quotient Therapeutics emphasize the healthcare industry's relevance.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Flagship Pioneering Inc. | PE Firm | Company | A bioplatform innovation company that incubates and fosters transformative scientific ventures. |
| Quotient Therapeutics | Target Company | Company | A pioneer in somatic genomics focused on novel drug discovery and targeting transformative medicines. |
| Rahul Kakkar, M.D. | CEO | People | Recently appointed CEO of Quotient Therapeutics and CEO-Partner at Flagship Pioneering, known for his leadership in biotech. |
| Jake Rubens, Ph.D. | Former CEO and Board Director | People | Co-founder and former CEO of Quotient Therapeutics, who will remain involved as a board director. |
| Noubar Afeyan, Ph.D. | Co-founder of Quotient Therapeutics | People | Founder and CEO of Flagship Pioneering and Co-founder of Quotient Therapeutics. |
| Geoffrey von Maltzahn, Ph.D. | Co-founder and Chairman of Quotient | People | Co-founder and Chairman of Quotient Therapeutics, General Partner at Flagship. |
| Pfizer | Collaboration Partner | Company | Engaged in collaboration agreements with Quotient Therapeutics in cardiovascular and renal diseases. |